Daily Archives: September 1, 2020

ImmunoBrain Checkpoint awarded Alzheimer’s Association grant to support Phase I trial investigating novel immunotherapeutic approach to treat Alzheimer’s disease

ImmunoBrain Checkpoint awarded Alzheimer’s Association grant to support Phase I trial investigating novel immunotherapeutic approach to treat Alzheimer’s disease

NEW YORK, Tuesday September 1, 2020 – ImmunoBrain Checkpoint Inc. (“IBC”) announced today that it has been awarded a $1,000,000 grant from the Alzheimer’s Association under the 2020 Part the Cloud-Bill Gates Partnership Grant Program to support a phase 1 clinical trial to examine safety and activity of its proprietary antibody, IBC-Ab002, targeted to enhance the immune system and induce brain repair processes in individuals with Alzheimer’s disease.

Currently there are no approved therapies for Alzheimer’s disease that can modify the disease course. IBC is developing treatments for neurodegenerative diseases by harnessing the power of the immune system to help protect and repair the brain. Based on studies pioneered by Professor Michal Schwartz at the Weizmann Institute of Science, demonstrating that the immune system is needed for the maintenance of healthy brain function and repair, but may be impaired in individuals with Alzheimer’s disease, IBC has developed a proprietary anti-PD-L1 antibody aimed to restore and boost the immune system to protect brain function.

If successful, IBC’s therapy will be a first-of-its kind approach to change the course of Alzheimer’s disease and arrest its progression. The success of this therapeutic approach would lead to a broad understanding of how the immune system helps protect the brain and would contribute to the understanding of the biology of Alzheimer’s disease.

“Seeing the robustness of the effect in so many animal models and on both symptoms and disease pathology, reinforces my optimism that we are activating a general mechanism needed for brain repair in these devastating conditions that will overcome many of the unique complexities of Alzheimer’s disease,” said Professor Schwartz, IBC’s Chief Scientist. “On a personal note, I am very grateful to the Part the Cloud program for its belief and support in our novel therapy.”

Dr. Jesse Cedarbaum, IBC’s Chief Medical Officer, said: “Aging is the major risk factor for the development of Alzheimer’s disease.  With aging comes the seemingly paradoxical phenomena of ‘inflammaging’ and ‘immune exhaustion and senescence’.  IBC-Ab002 is an antibody that has been designed to rebalance the immune system to provide neuroprotection in Alzheimer’s disease and perhaps other neurodegenerative disorders. We thank the Alzheimer’s Association-Bill Gates partnership for its recognition that augmenting the body’s natural defenses could be an important avenue for treating Alzheimer’s disease.”

Dr. Philip Scheltens, Director of the Alzheimer Center at the VU University Medical Center in Amsterdam and IBC’s Phase 1 study Principal Investigator, said: “I am pleased that the Alzheimer’s Association Part the Cloud partnership recognizes the innovative approach of IBC, supporting its progress to the clinic. I am confident that these funds will help the IBC team to progress its therapeutic target through the clinical study here at Amsterdam UMC.”

About ImmunoBrain Checkpoint

ImmunoBrain Checkpoint (IBC) is a biopharmaceutical company developing novel disease-modifying immune therapies to combat neurodegenerative diseases, and in particular, Alzheimer’s disease. IBC’s IP platform emerged from the lab of Prof. Michal Schwartz and licensed from Yeda, the commercialization arm of the Weizmann Institute. IBC’s technology is based on more than 20 years of studies by Schwartz’s team, who pioneered the idea that the brain engages in a life-long healthy dialogue with the immune system for its maintenance and repair, and that this communication is compromised in aging and Alzheimer’s disease. Schwartz’s team has demonstrated that loosening the restraints from the immune system using antibodies that target inhibitory immune checkpoints (commonly expressed by exhausted immune cells), can rewire brain/immune communication, and thereby protect the brain from functional loss.

In January 2020 IBC received a $500,000 grant from the ALS Association to pursue a novel immunotherapeutic approach to treat ALS and identify optimal immune-checkpoint pathways to target. www.ibcheckpoint.com

About IBC-Ab002

IBC-Ab002 is a proprietary antibody developed by IBC to target restraining immune system molecules, and thereby enable a neuroprotective immunological cascade to combat the effects of neurodegenerative proteinopathy. The antibody has been specifically optimized for IBC’s therapeutic mechanism of action. In preclinical studies, anti-PD-L1 treatment was found to be effective in four different models of Alzheimer’s disease, including both amyloid and tau transgenic mice. In these studies, anti-PD-L1 antibody treatment reduced both cognitive deficits and toxic pathological proteins that accumulate in the brain. It is the first therapy to harness the body’s own immune mechanism of repair to rewire the communication between the body and the brain.

IBC-Ab002 has also been shown to have an improved safety profile relative to other antibodies of this family with respect to inducing immune-mediated adverse effects in mouse models. IBC plans to start its first-in-human clinical trial in Q4 2021 in patients with early Alzheimer’s disease.

About the Part the Cloud-Gates Partnership Grant Program

As the world’s largest nonprofit funder of Alzheimer’s research, the Alzheimer’s Association is committed to accelerating the global effort to eliminate Alzheimer’s. The Association’s Part the Cloud program aims to accelerate the translation of possible therapeutics in the clinical setting. Bill Gates and Part the Cloud have partnered to accelerate research exploring specific areas of neurodegeneration, neuroinflammation, and immune responses that contribute to the development of Alzheimer’s and dementia. For more information, visit http://www.alz.org/speed

For more information, please contact

Consilium Strategic Communications

Sukaina Virji / David Daley / Lucy Featherstone / Maya Bennison

Immunobrain@consilium-comms.com

Intuitive, integrated and efficient – world premiere of Philips’ next-generation Azurion image-guided therapy platform

September 1, 2020

  • New level of integration across imaging, physiology, hemodynamic and informatics applications
  • SmartCT guides acquisition of 3D CT-like images and provides visualization and measurement tools
  • Increased efficiency and flexibility with tableside access to more modalities and intuitive control of the gantry

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced its next-generation Philips Azurion image-guided therapy platform, marking an important step forward in optimizing clinical and operational lab performance and expanding the role of image-guided interventions in the treatment of patients. Intuitive, integrated and efficient, the next-generation Azurion advances the capabilities of the platform to further improve the quality and efficiency of interventional procedures. The Azurion platform has already achieved rapid global adoption and has been used in well over two million procedures [1] worldwide since its introduction three years ago.

In the past few decades, clinical practices around the world have evolved to successfully treat more patients and perform more complex procedures in interventional labs. However, with more staff and technologies involved during these procedures, interventional lab environments can become crowded and cluttered. In order to enhance clinician focus and control during procedures, Philips has integrated all the essential lab systems and tools into this new version of the Azurion platform, making it an important step forward in lab integration.

An industry-first, the Philips Azurion image-guided therapy platform now integrates control of imaging, physiology, hemodynamic and informatics applications, as well as intuitive control of the gantry, at the tableside, allowing clinicians to control all compatible applications from a single touch screen while performing procedures. This can eliminate the need for clinicians to leave the sterile field and step into an adjacent control room, as well as supporting faster and better informed decision making.

Simplifying 3D imaging during interventional procedures
With this next-generation Azurion platform, Philips is also introducing a new 3D imaging solution called SmartCT [2]. With SmartCT, users are guided through the image acquisition and can review and interact with the acquired CT-like 3D images on the tableside touch screen module using 3D visualization and measurement tools. These tools have been designed to support procedures in a range of clinical domains, including neurology, oncology, and cardiovascular procedures. The use of 3D imaging such as 3D RA or Cone Beam CT during interventional procedures has been shown to improve outcomes [3] and reduce radiation dose for both staff and patients [4].

“Our aim as an innovation company and global market leader in image-guided therapy is to push the boundaries and set new industry standards for delivering an outstanding experience for clinicians, helping them to deliver superior care to every patient,” said Ronald Tabaksblat, General Manager Image Guided Therapy Systems at Philips. “This next-generation Azurion makes routine cardiovascular procedures more efficient and supports the development of new minimally-invasive techniques to treat complex diseases such as stroke, lung cancer and spine disorders.”

“The integrated platform enables us to efficiently carry out complex interventions at any time using a wide range of functions such as IVUS and iFR co-registration,” said Dr. med. Alexander Becker, head of the cardiac catheter laboratory at the Robert Bosch Hospital in Stuttgart, Germany, and one of the first hospitals to experience the new platform. “The use of the control panel by the examiner is intuitive, combining different sources of information to make patient evaluation much easier and faster.”

Seamless control and workflow during procedures
With the new Azurion platform, clinicians can easily switch between imaging, physiology, hemodynamic and informatics applications, including SmartCT and IntraSight – a comprehensive suite of clinically proven iFR, FFR, IVUS and co-registration modalities. Fully automatic position control enables clinicians to intuitively control the position of the gantry and table, as well as choosing from a wide range of stored parameters. The new Azurion also includes advanced cybersecurity features, new high-definition image display capabilities, and advanced remote and proactive services. The platform is available in three versions: complementing the Azurion 3 and 7 variants, Philips now also offers the Azurion 5 to facilitate even more tailored solutions to address specific customer needs. For more information visit www.philips.com/azurion.

[1] Based on Philips’ internal case and procedure data.
[2] SmartCT is 510(k) pending and not available for sale in the USA.
[3] Miyayama et al., ‘Comparison of local control in transcatheter arterial chemoembolization of hepatocellular carcinoma ≤6 cm with or without intraprocedural monitoring of the embolized area using cone beam computed tomography’, CVIR 2014.
[4] Schott et al., ‘Radiation dose in prostatic artery embolization using Cone Beam CT and 3D roadmap software, JVIR 2019.

For further information, please contact:

Mark Groves
Philips Global Press Office
Tel: +31 631 639 916
Email: mark.groves@philips.com

Twitter: mark_groves

Fabienne van der Feer
Philips Image Guided Therapy
Tel: +31 622 698 001
Email: fabienne.van.der.feer@philips.com

Twitter: FC_Feer

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

Relay Medical and Fio Corporation Announce Signing Distribution Partners in U.S. & France for the Fionet Mobile COVID-19 Testing and Tracking Platform

Fionet real-time linkage

Fionet mobile devices and web portal

  • Relay and Fio announce distribution partners in U.S. and France to market Fionet to pharmacies and certain other sectors
  • With 10x more locations than hospitals, Pharmacies are well-positioned to dramatically improve how countries manage COVID-19 testing
  • Fionet is a first-of-its-kind mobile testing platform to manage and track community-based COVID-19 testing
  • Fionet Devices, usable by non-expert personnel, enables lab-grade diagnostic testing in pharmacies, workplaces, airports, clinics, nursing homes and other community-based locations
  • Simultaneously, Fionet Cloud relays real-time data for remote oversight of frontline testing activities and results

TORONTO, Aug. 31, 2020 (GLOBE NEWSWIRE) — Relay Medical Corp. (“Relay” or the “Company”) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2), and Fio Corporation (“Fio”) announce the signing of U.S. and French distribution partners for the Fionet Mobile COVID-19 testing and tracking platform.

Relay and Fio previously announced a joint venture on August 19, 2020 to rapidly launch and deploy a new COVID-19 testing, data collection and reporting solution. The JV operates under the name “Fionet Rapid Response Group” (FRR) and is headquartered in Toronto, Canada. On August 25, Relay and Fio announced the commencement of FRR operations.

Today, FRR announces that Fio has signed distribution partners in France and in the U.S. to market Fionet to pharmacies and certain other sectors.

Pharmacies are community-based and thereby access the vast majority of the population; they are approximately 10x more numerous than clinics; and France, the UK, and the U.S. have already legalized COVID testing in pharmacies, and other countries are following suit. Pharmacies are well-positioned to deliver effective mass testing and triage and for safe return to work programs.

For example, the U.S. has 67,000 community pharmacies, dwarfing the 7,000 hospitals and community health centres combined. The U.S.’s 175,000 pharmacists are referred to as the most over-trained and under-utilized healthcare professionals in America.1

Fionet Process

Fionet’s workflow

In France, Fionet will be distributed by Magentine, a company set up to distribute Fionet and rapid diagnostic tests (RDTs). In exchange for its marketing rights, Magentine has committed to a minimum order in 2021. Magentine was founded and is headed by Mr. Francois Dupoteau, who previously co-founded a successful in vitro diagnostic company, ECS Prograstrin. In addition to marketing Fionet to pharmacies, Magentine will market Fionet to physicians’ offices.

“Magentine Healthcare chose to deploy the Fionet Platform in France to support the new opportunities for pharmacies to use RDT tests. Fionet is the perfect solution for pharmacists to accurately read, trace, and monitor rapid tests. Fionet further creates efficient links between RDT users, central labs, and patients to create maximum value for all stakeholders,” said Francois Dupoteau, CEO of Magentine.

In the U.S., Fionet will be distributed by MyLabBox, a company which is a leader of at-home and in-store testing solutions. In exchange for its marketing rights, Magentine has committed to a minimum order in 2021. In addition to marketing Fionet to U.S. pharmacies, MyLabBox will market Fionet to corporations seeking to implement safe-return-to-work testing programs.

“To get people back to work, to get them bringing home paycheques again, to protect the economy, the question is not who is sick. It is who is well and how can they return safely to work. Pharmacies are an ideal site for mass community-based testing, so that personnel can be tested and feel secure that everyone else in their workplace was also tested,” said Dr Michael Greenberg, CEO of Fionet Rapid Response Group and CEO of Fio Corporation.

“With Fionet,” said Yoav Raiter, CEO, Relay Medical Corp, “there can be accurate, frontline testing, real-time tracking, remote supervision of frontline action, and automated digitization for all frontline activity – all essential for the mass, decentralized testing that could be done in sites such as pharmacies in order to return people safely to work and to protect the economy from continued damage.”

Fionet is a mobile testing and tracking platform that enables community-based return-to-work programs by performing at hospital-grade accuracy, yet in higher volume, faster-speed, and with less-skilled frontline workers.

Fionet thus enables the controlled expansion of diagnostic testing and triage beyond the few overburdened medical centres to the many community-based settings such as pharmacies, small clinics, workplaces, airports, nursing homes, schools, etc.

The platform combines handheld devices linked to online AI-powered cloud, automating frontline testing and capturing test results for tracking. Rugged, mobile devices are compatible with multiple third-party antigen and antibody COVID-19 rapid diagnostic tests (RDTs), which creates sourcing flexibility for RDTs which are of limited supply and continuously evolving. Fionet also connects with molecular testing devices such as PCRs.

Fio’s cloud-platform delivers real-time, actionable intelligence for supervisors and public health officials to manage responses and resources to new levels of precision and promptness. Data and insights are delivered to dashboards, IT systems and public health databases for rapid, secure and data-informed responses.

Fionet has a proven, positive impact on 1 million patients with infectious diseases in over a dozen countries and 4 continents. Fio successfully managed testing programs for high-consequence diseases such as malaria, HIV, dengue and ebola in partnership with world-class organizations including World Health Organization, Bill & Melinda Gates foundation, Ministry of Health of Democratic Republic of Congo (DRC) and Republic of Kenya Ministry of Health.

1 https://theconversation.com/us-pharmacists-can-now-test-for-coronavirus-they-could-do-more-if-government-allowed-it-135188

**The Companies are not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.

About Fio Corporation

Fio Corporation, privately held and headquartered in Toronto, developed and markets the world’s first integrated guidance & tracking IT platform for decentralized healthcare settings, a new category of solution that raises healthcare quality and lowers healthcare costs. The platform enables average healthcare workers in clinics to deliver a new level of quality-controlled diagnostic testing and case management. Simultaneously, as an automated by-product of its clinical use, the platform captures and provides unprecedented frontline data to remote supervisors and stakeholders, enabling real-time remote tracking, insight distribution, and intervention. Fio operates globally in partnership with local distribution, service, and support organizations and also partners with other companies that license its technologies.

Website: www.fio.com

About Relay Medical Corp.

Relay Medical is a MedTech innovation Company headquartered in Toronto, Canada focused on the development of novel technologies in the diagnostics and AI data science sectors.

Website: www.relaymedical.com

Contact:
W. Clark Kent
President
Relay Medical Corp.
Office. 647-872-9982 ext. 2
TF. 1-844-247-6633 ext. 2
investor.relations@relaymedical.com

Bernhard Langer
EU Investor Relations
Office. +49 (0) 177 774 2314
Email: blanger@relaymedical.com

Forward-looking Information Cautionary Statement

Except for statements of historic fact, this news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company’s control. There are no assurances that the commercialization plans for HemoPalm Corp. described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which filings are available at www.sedar.com

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/d18b0ef3-be59-45a1-bf07-47c75948f5d3

https://www.globenewswire.com/NewsRoom/AttachmentNg/be5d8225-797f-4d2d-8116-464e5fe7ade1

Cavonix Enables Autonomous Vehicles with LeddarTech’s Leddar Pixell LiDAR Technology

QUEBEC CITY, Sept. 01, 2020 (GLOBE NEWSWIRE) — LeddarTech®, a leader in ADAS and AD sensor technology, is pleased to announce that Cavonix Ltd. has selected the Leddar™ Pixell sensor technology for its autonomous shuttles and off-road trucking customers.

Cavonix Ltd. is a tech start-up based in the United Kingdom that has developed a range of white-label autonomous control systems for several vehicle manufacturers and technology companies. Together with their parent company Aim Technologies, who are world leaders in motorsports electronics, Cavonix has recently developed a range of new technologies for the autonomous shuttle, off-road, and agriculture sectors.

LeddarTech markets the only truly open, flexible, and scalable sensing platform for all automotive and mobility applications. The platform delivers key ADAS & AD system components and customizable reference solutions and enables extensibility from L1 (camera & radar) to L5 (multiple sensor modalities including LiDAR) at optimal performance and cost. Platform components include a modular sensor fusion and perception software stack, the LeddarEngine™ (SoCs and signal processing software) and LiDAR sensors like the Leddar Pixell, that was developed for the mobility market and exhibits the technology of the LeddarEngine.

“Cavonix chose LeddarTech’s technology because of its ability to deliver enhanced safety for our customers,” stated Steven Lake, Founder and CEO. “The robustness and reliability of LeddarTech’s solid-state technology meets today’s demanding mobility conditions and makes it the technology of choice toward preventing collisions in stop-and-go applications by eliminating dead zones left by other sensing technologies.” Mr. Lake continued: “At Cavonix, we are committed to providing robust solutions for real-world applications – science without the fiction.”

“We are honored that our LiDAR solutions were selected and trusted by Cavonix to support its autonomous shuttle and off-road trucking customers,” stated Frantz Saintellemy, President and COO of LeddarTech. Mr. Saintellemy continued, “What Cavonix has been able to achieve in a relatively short period is impressive, and we look forward to their future developments using LeddarTech technologies.” Mr. Saintellemy concluded that “making mobility applications safer is at the core of our strategy. Our technology offers the right balance of performance and cost-effectiveness and is ready for deployment today.”

About Cavonix Ltd.

Cavonix specializes in mobile autonomy, navigation, and perception for the development of autonomous vehicles with three business functions:

  • CAVLab is real-time development software for control of connected autonomous vehicles.
  • CavSense fusion processing allows vehicles to collect real-time data from their surroundings and enables vehicles to navigate in controlled environments whilst route planning and avoiding obstacles.
  • CavTrak fleet management telemetry system allows the data collected to be monitored in real time and shared between vehicles and control.

The parent company of Cavonix is Aim Technologies Group. Aim Technologies design, develop, and manufacture world-class racing data logging and timing equipment to supply thousands of championships and race teams globally. Aim Technology products are engineered to deliver the accurate data needed to improve driver and vehicle performance to win races. The solutions are highly regarded as the de-facto industry standard in data acquisition technology and offer dual use for track and road. With a wide range of solutions, from displays and data loggers to camera systems and sensors. All the products are engineered to enhance the competitive performance of race teams, and their solutions are developed to be tailored to their clients’ exact requirements, always with their desired outcomes in mind.

Additional information about Cavonix is accessible at www.cavonix.com and via the parent company Aim Technology Group on LinkedIn, Twitter, Facebook, and YouTube.

Contact:
Steven Lake, Director and CEO of Cavonix
+44 (0) 1773-459252
info@cavonix.com

About LeddarTech
LeddarTech is a leader in environmental sensing solutions for autonomous vehicles and advanced driver assistance systems. Founded in 2007, LeddarTech has evolved to become a comprehensive end-to-end environmental sensing company by enabling customers to solve critical sensing and perception challenges across the entire value chain of the automotive and mobility market segments with its LeddarVision™ sensor-fusion and perception platform. LeddarTech delivers a cost-effective, scalable, and versatile LiDAR development solution to Tier 1-2 automotive system integrators that enables them to develop automotive-grade solid-state LiDARs based on the foundation of the LeddarEngine™. LeddarTech has 14 generations of solid-state LiDARs based on the LeddarEngine platform operating 24/7 in harsh environments. This platform is actively deployed in autonomous shuttles, trucks, buses, delivery vehicles, smart cities/factories, and robotaxi applications. The company is responsible for several innovations in cutting-edge automotive and mobility remote-sensing applications, with over 80 patented technologies (granted or pending) enhancing ADAS and autonomous driving capabilities.

Additional information about LeddarTech is accessible at www.leddartech.com and on LinkedIn, Twitter, Facebook, and YouTube.

Contact:
Daniel Aitken, Vice-President, Global Corporate Marketing and Communications, LeddarTech Inc.
Tel.: + 1-418-653-9000 ext. 232
daniel.aitken@leddartech.com

Leddar, LeddarTech, LeddarEngine, LeddarVision, LeddarSP, LeddarCore, VAYADrive, VayaVision, and related logos are trademarks or registered trademarks of LeddarTech Inc. and its subsidiaries. All other brands, product names, and marks are or may be trademarks or registered trademarks used to identify products or services of their respective owners.

Cavonix เปิดใช้งานยานยนต์อัตโนมัติด้วยเทคโนโลยี Leddar Pixell LiDAR ของ LeddarTech

ควิเบก ซิตี้, Sept. 01, 2020 (GLOBE NEWSWIRE) — LeddarTech® ผู้นำด้านเทคโนโลยีเซ็นเซอร์ ADAS และ AD ยินดีที่จะประกาศว่า Cavonix Ltd. ได้เลือกเทคโนโลยีเซ็นเซอร์ Leddar™ Pixell สำหรับบริการรถรับส่งอัตโนมัติและลูกค้าที่ใช้งานรถบรรทุกนอกถนนของบริษัท

Cavonix Ltd. เป็นบริษัทสตาร์ทอัพด้านเทคโนโลยีที่ตั้งอยู่ในสหราชอาณาจักรซึ่งได้พัฒนาระบบควบคุมอัตโนมัติแบบป้ายขาว (White-Label) สำหรับผู้ผลิตยานพาหนะและบริษัทเทคโนโลยีหลายราย เมื่อไม่นานมานี้ Cavonix ได้พัฒนาเทคโนโลยีใหม่มากมายสำหรับรถรับส่งขับขี่อัตโนมัติ การใช้งานนอกถนน และภาคส่วนเกษตรกรรมร่วมกับบริษัทแม่ของตน ซึ่งก็คือ Aim Technologies ซึ่งเป็นผู้นำระดับโลกด้านมอเตอร์สปอร์ตอิเล็กทรอนิกส์

LeddarTech ทำการตลาดแพลตฟอร์มการตรวจจับที่เปิดกว้าง ยืดหยุ่น และปรับขนาดได้อย่างแท้จริงสำหรับการใช้งานด้านยานยนต์และการเคลื่อนที่ทั้งหมด แพลตฟอร์มนี้ส่งมอบส่วนประกอบระบบ ADAS และ AD ที่สำคัญและโซลูชันอ้างอิงที่ปรับแต่งได้และช่วยให้สามารถขยายได้จาก L1 (กล้องและเรดาร์) ถึง L5 (รูปแบบของเซ็นเซอร์ที่หลากหลายรวมถึง LiDAR) ด้วยประสิทธิภาพและต้นทุนที่เหมาะสม ส่วนประกอบแพลตฟอร์มประกอบด้วยการรวมสัญญาณเซ็นเซอร์แบบแยกส่วนและชุดซอฟต์แวร์การรับรู้ LeddarEngine™ (SoC และซอฟต์แวร์ประมวลผลสัญญาณ) และเซ็นเซอร์ LiDAR อย่าง Leddar Pixell ซึ่งได้รับการพัฒนาขึ้นเพื่อตลาดการเคลื่อนที่และแสดงให้เห็นถึงเทคโนโลยีของ LeddarEngine

“Cavonix เลือกเทคโนโลยีของ LeddarTech เนื่องจากความสามารถในการส่งมอบความปลอดภัยที่ดียิ่งขึ้นสำหรับลูกค้าของเรา” Steven Lake ผู้ก่อตั้งและ CEO กล่าว “ความทนทานและความน่าเชื่อถือของเทคโนโลยีโซลิดสเตตของ LeddarTech ตรงตามเงื่อนไขความต้องการด้านการเคลื่อนที่ในปัจจุบันและทำให้เทคโนโลยีนี้เป็นทางเลือกในการป้องกันการชนกันในการใช้งานแบบ Stop-and-Go โดยการกำจัดจุดบอดที่เกิดจากเทคโนโลยีตรวจจับอื่นๆ” Mr. Lake กล่าวต่อว่า: “ที่ Cavonix เรามุ่งมั่นที่จะมอบโซลูชันที่แข็งแกร่งสำหรับการใช้งานจริงทางวิทยาศาสตร์โดยไม่อิงนิยาย”

“เรารู้สึกเป็นเกียรติอย่างยิ่งที่โซลูชัน LiDAR ของเราได้รับการคัดเลือกและได้รับความไว้วางใจจาก Cavonix เพื่อสนับสนุนรถรับส่งอัตโนมัติและลูกค้าที่ใช้งานรถบรรทุกนอกถนนของบริษัท” Frantz Saintellemy ประธานและ COO ของ LeddarTech กล่าว Mr. Saintellemy ยังกล่าวต่อว่า “สิ่งที่ Cavonix สามารถทำให้สำเร็จได้ในระยะเวลาอันสั้นเป็นที่น่าประทับใจ และเราตั้งตารอคอยการพัฒนาในอนาคตของพวกเขาโดยใช้เทคโนโลยี LeddarTech” Mr. Saintellemy สรุปว่า “การทำให้การใช้งานการเคลื่อนที่ปลอดภัยขึ้นเป็นหัวใจของกลยุทธ์ของเรา เทคโนโลยีของเรามอบความสมดุลที่เหมาะสมระหว่างประสิทธิภาพและความคุ้มค่าและพร้อมสำหรับการปรับใช้ในปัจจุบัน”

เกี่ยวกับ Cavonix Ltd.

Cavonix เชี่ยวชาญด้านการเคลื่อนที่อัตโนมัติ การนำทาง และการรับรู้สำหรับการพัฒนายานยนต์อัตโนมัติพร้อมด้วยฟังก์ชันทางธุรกิจสามประการ:

  • CAVLab คือซอฟต์แวร์การพัฒนาแบบเรียลไทม์สำหรับการควบคุมยานยนต์อัตโนมัติที่ได้รับการเชื่อมต่อ
  • การประมวลผลแบบฟิวชัน CavSense ช่วยให้ยานพาหนะเก็บข้อมูลแบบเรียลไทม์จากสภาพแวดล้อมและช่วยให้ยานพาหนะนำทางในสภาพแวดล้อมที่มีการควบคุมในขณะที่มีการวางแผนเส้นทางและหลีกเลี่ยงสิ่งกีดขวาง
  • ระบบการตรวจวัดระยะไกลในการจัดการยานพาหนะ CavTrak ช่วยให้ข้อมูลที่รวบรวมได้รับการตรวจสอบแบบเรียลไทม์และแบ่งปันระหว่างยานพาหนะและการควบคุ

บริษัทแม่ของ Cavonix คือ Aim Technologies Group Aim Technologies ออกแบบ พัฒนา และผลิตอุปกรณ์บันทึกและจับเวลาข้อมูลการแข่งรถระดับโลกเพื่อจัดจำหน่ายให้กับการแข่งขันชิงแชมป์และทีมแข่งหลายพันทีมทั่วโลก ผลิตภัณฑ์ของ Aim Technology ได้รับการออกแบบมาเพื่อส่งมอบข้อมูลที่แม่นยำซึ่งจำเป็นในการพัฒนาผู้ขับขี่และประสิทธิภาพของยานพาหนะเพื่อชนะการแข่งขัน โซลูชันนี้ได้รับการยกย่องอย่างสูงว่าเป็นมาตรฐานอุตสาหกรรมที่ได้รับการยอมรับในด้านเทคโนโลยีการเก็บข้อมูลและนำเสนอการใช้งานแบบคู่สำหรับในสนามและถนน ด้วยโซลูชันที่หลากหลาย ตั้งแต่จอแสดงผลและตัวบันทึกข้อมูลไปจนถึงระบบกล้องและเซ็นเซอร์ ผลิตภัณฑ์ทั้งหมดได้รับการออกแบบมาเพื่อเพิ่มประสิทธิภาพในการแข่งขันของทีมแข่ง และโซลูชันของพวกเขาได้รับการพัฒนาเพื่อปรับให้เหมาะกับความต้องการที่แน่นอนของลูกค้า โดยคำนึงถึงผลลัพธ์ที่ต้องการเสมอ

สามารถดูข้อมูลเพิ่มเติมเกี่ยวกับ Cavonix ได้ที่ www.cavonix.com และผ่านทางบริษัทแม่ Aim Technology Group บน LinkedInTwitterFacebook และ YouTube

ติดต่อ:
Steven Lake กรรมการและ CEO ของ Cavonix
+44 (0) 1773-459252
info@cavonix.com

เกี่ยวกับ LeddarTech
LeddarTech เป็นผู้นำในด้านโซลูชันการตรวจจับสภาพแวดล้อมสำหรับยานยนต์อัตโนมัติและระบบช่วยเหลือผู้ขับขี่ขั้นสูง LeddarTech ก่อตั้งในปี 2007 โดยได้พัฒนาเป็นบริษัทการตรวจจับสภาพแวดล้อมแบบครบวงจรโดยให้ลูกค้าสามารถแก้ไขปัญหาการตรวจจับและการรับรู้ที่สำคัญได้ทั่วทั้งห่วงโซ่คุณค่าของตลาดยานยนต์และการเคลื่อนที่ด้วยแพลตฟอร์มการรวมข้อมูลเซ็นเซอร์และการรับรู้ของร้าน LeddarVision™ LeddarTech มอบโซลูชันการพัฒนา LiDAR ที่มีความยืดหยุ่น ปรับขนาดได้ และหลากหลายให้กับผู้วางระบบยานยนต์ระดับ Tier 1-2 ที่ช่วยให้พวกเขาสามารถพัฒนา LiDAR แบบโซลิดสเตตระดับยานยนต์บนพื้นฐานของ LeddarEngine™ LeddarTech มี LiDAR แบบโซลิดสเตต 14 รุ่นซึ่งใช้แพลตฟอร์ม LeddarEngine ที่ทำงานทุกวันตลอด 24 ชั่วโมงในสภาพแวดล้อมที่เลวร้าย แพลตฟอร์มนี้ได้รับการปรับใช้ในการใช้งานรถรับส่งขับขี่อัตโนมัติ รถบรรทุก รถโดยสารประจำทาง รถส่งสินค้า เมือง/โรงงานอัจฉริยะ และแท็กซี่ไร้คนขับ บริษัทเป็นผู้รับผิดชอบในการคิดค้นนวัตกรรมใหม่ๆ ในแอปพลิเคชันตรวจจับยานยนต์และการเคลื่อนที่ระยะไกลที่ทันสมัยด้วยเทคโนโลยีที่จดสิทธิบัตรมากกว่า 80 รายการ (จดสิทธิบัตรแล้วหรือรอดำเนินการ) ที่ช่วยเสริมขีดความสามารถ ADAS และการขับขี่แบบอัตโนมัติ

สามารถดูข้อมูลเพิ่มเติมเกี่ยวกับ LeddarTech ได้ที่ www.leddartech.com และบน LinkedInTwitterFacebook และ YouTube

ติดต่อ:
Daniel Aitken รองประธานฝ่ายการตลาดและการสื่อสารองค์กรระดับโลกของ LeddarTech Inc.
โทร: + 1-418-653-9000 ext. 232
daniel.aitken@leddartech.com

Leddar, LeddarTech, LeddarEngine, LeddarVision, LeddarSP, LeddarCore, VAYADrive, VayaVision และโลโก้ที่เกี่ยวข้องเป็นเครื่องหมายการค้าหรือเครื่องหมายการค้าจดทะเบียนของ LeddarTech Inc. และบริษัทในเครือ แบรนด์ ชื่อผลิตภัณฑ์ และเครื่องหมายต่างๆ ทั้งหมดเป็นหรืออาจเป็นเครื่องหมายการค้าที่ใช้เพื่อระบุถึงผลิตภัณฑ์หรือบริการต่างๆ ของเจ้าของที่เกี่ยวข้อง